

Cross-talk between immune system and microbiota in COVID-19

Shaghayegh Baradaran Ghavami, Mahsa Pourhamzeh, Maryam Farmani, Shahrbanoo Keshavarz Azizi Raftar, Shabnam Shahrokh, Anastasia Shpichka, Hamid Asadzadeh Aghdai, Mojdeh Hakemi-Vala, Nikoo Hossein-khannazer, Peter Timashev & Massoud Vosough

To cite this article: Shaghayegh Baradaran Ghavami, Mahsa Pourhamzeh, Maryam Farmani, Shahrbanoo Keshavarz Azizi Raftar, Shabnam Shahrokh, Anastasia Shpichka, Hamid Asadzadeh Aghdai, Mojdeh Hakemi-Vala, Nikoo Hossein-khannazer, Peter Timashev & Massoud Vosough (2021) Cross-talk between immune system and microbiota in COVID-19, Expert Review of Gastroenterology & Hepatology, 15:11, 1281-1294, DOI: [10.1080/17474124.2021.1991311](https://doi.org/10.1080/17474124.2021.1991311)

To link to this article: <https://doi.org/10.1080/17474124.2021.1991311>



Published online: 02 Nov 2021.



Submit your article to this journal [↗](#)



Article views: 531



View related articles [↗](#)



View Crossmark data [↗](#)



Citing articles: 1 View citing articles [↗](#)

REVIEW



Cross-talk between immune system and microbiota in COVID-19

Shaghayegh Baradaran Ghavami^{a,*}, Mahsa Pourhamzeh^{b,c,*}, Maryam Farmani^a, Shahrbanoo Keshavarz Azizi Raftar^a, Shabnam Shahrokh^a, Anastasia Shpichka^{d,e,f}, Hamid Asadzadeh Aghdaei^a, Mojdeh Hakemi-Vala^g, Nikoo Hossein-khannazer^a, Peter Timashev^{d,e,f} and Massoud Vosough^b

^aBasic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^bDepartment of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; ^cDivision of Neuroscience, Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran; ^dInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University, Moscow, Russia; ^eWorld-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University, Moscow, Russia; ^fChemistry Department, Lomonosov Moscow State University, Moscow, Russia; ^gDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT

Introduction: Human gut microbiota plays a crucial role in providing protective responses against pathogens, particularly by regulating immune system homeostasis. There is a reciprocal interaction between the gut and lung microbiota, called the gut-lung axis (GLA). Any alteration in the gut microbiota or their metabolites can cause immune dysregulation, which can impair the antiviral activity of the immune system against respiratory viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2.

Areas covered: This narrative review mainly outlines emerging data on the mechanisms underlying the interactions between the immune system and intestinal microbial dysbiosis, which is caused by an imbalance in the levels of essential metabolites. The authors will also discuss the role of probiotics in restoring the balance of the gut microbiota and modulation of cytokine storm.

Expert opinion: Microbiota-derived signals regulate the immune system and protect different tissues during severe viral respiratory infections. The GLA's equilibration could help manage the mortality and morbidity rates associated with SARS-CoV-2 infection.

ARTICLE HISTORY

Received 16 June 2021
Accepted 6 October 2021

KEYWORDS

Gut microbiota; gut microbial-host-immune axis; gut-lung axis; coronavirus; Covid-19; respiratory complications

1. Introduction

Influenza and other respiratory virus infections are one of the leading causes of morbidity and mortality worldwide [1]. A competent immune system reduces mortality by protecting the host against viral infections and reducing susceptibility to secondary bacterial infections [2]. The World Health Organization (WHO) has stated that severe coronavirus disease 2019 (COVID-19) is a pandemic challenge [3]. COVID-19 is a lethal condition in patients with comorbidity, particularly those with immune system disorders. A healthy immune system can help people overcome clinical complications and return to work faster [4]. COVID-19 seems to cause a wide range of extrapulmonary difficulties affecting multiple organ systems. The pooled prevalence of all gastrointestinal (GI) problems was 17.6% in an early meta-analysis of 60 trials involving 4243 patients, most of whom were from China. The most prevalent presenting symptom was anorexia (26.8%), followed by diarrhea (12.5%), nausea/vomiting (10.2%), and abdominal pain (9.2%) [5]. Critically ill COVID-19 patients

often develop GI complications during hospitalization, such as bowel ischemia, pancreatitis, GI bleeding, elevated transaminases, Ogilvie syndrome, and severe ileus [6,7].

Gut microbiota is essential for the development of immune responses [8]. There are approximately 38 trillion microorganisms in our body, including bacteria, fungi, archaea, viruses, and other eukarya. Bacteria are more common among them, with at least 2,000 different species [9]. The gastrointestinal tract (GIT) is the main habitat of microbiota, since it provides the largest interface surface (250–400 m²) of the body and is nutrient-rich. The GIT comprises over 2,000 bacteria species from 12 distinct phyla. The microbiome contains 3 million genes that are 150 to 500 times more than the number of genes in the human genome [10]. The gut microbiota can affect food digestion, production of energy and vitamins (B1, B5, B12, K, and folic acid), biliary acids deconjugation, and other vital biochemical aspects of our life [11,12]. On the other hand, microbiota has a remarkable impact on the activation and function of immune cells. Accordingly, a persistent microbial community imbalance in the gut is known as

CONTACT Peter Timashev ✉ timashev.peter@gmail.com 📠 Institute for Regenerative Medicine, Sechenov University, 8-2 Trubetskaya street 119991, Moscow, Russia;

Massoud Vosough ✉ masvos@Royaninstitute.org 📠 Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Royan Alley, Hafez Street, Banihashem Street, Soleimani Avenue, Tehran, Iran

*These authors contributed equally to this paper.

Article highlights

- Gut microbiota is essential for host immune system's induction, education, function, development of immune responses, and regulates the integrity of the mucosal barrier, provides bacterial metabolites, and regulates the immunoregulatory functions of intestinal epithelial cells by modulating the expression of antimicrobial factors.
- Dysbiosis is linked to dysimmunity, commonly described as a T-helper 2 (Th2)-overactive, and Treg-deficient state.
- Cross-talk between the healthy gut microbiota and lungs can significantly prevent respiratory tract infection in both influenza A virus and COVID-19 through reciprocal interaction, quorum-sensing molecules, and synthesis of antimicrobial agents.
- In COVID-19 patients, probiotic treatment could result in an eight-fold lower rate of respiratory failure.
- It seems that fecal microbiota transplantation could be used as a therapeutic and rehabilitative intervention in the COVID-19 patients.

dysbiosis [13], increasing the risk of infections and autoimmune diseases [14–19].

Many studies have recently shown a regulatory association between the gut microbiota and other organs, such as the gut–lung axis, gut–brain axis [20], gut–liver axis [21], gut–host hormonal axis [22], and gut–skin axis [23]. Noticeably, cross-talk between the healthy gut microbiota and lungs can significantly prevent respiratory tract infection in both influenza A virus and COVID-19 [24,25]. Based on these interactions, any alterations in the gut microbiota may directly affect the function of other organs. Furthermore, more than 50% of patients with inflammatory bowel disease (IBD) and 33% of patients with irritable bowel syndrome (IBS) are susceptible to respiratory complications as a result of dysbiosis without a history of acute or chronic respiratory disease [26,27].

The interaction of the gut microbiome and immune system [10] plays a protective role in preventing severe infection and controlling the viral load. The immune system is naïve in newborns and inefficient in older adults. Both groups are susceptible to viral infections and have a high mortality rate [28,29]. Recent molecular studies have also revealed differences in gut microbiota composition among infants, toddlers, adults, and the elderly [30]. It appears that an altered gut microbiota composition can make an infant more susceptible to infections and allergic disease [31]. Dysbiosis, or disruptions in the hemostasis of gut microbiota, may cause an uncontrolled and intense immune response to viral infections. Dysbiosis occurs when there is disparity in the number of normal bacteria and a rise in commensal, and/or opportunistic gut bacteria. Moreover, eubiosis is characterized by a species diversity dominated by members of only four bacterial phyla, including Firmicutes (e.g. *Lactobacillus* and *Clostridium*), Bacteroidetes (e.g. *Bacteroides*), Proteobacteria (e.g. *Escherichia*), and Actinobacteria (e.g. *Bifidobacterium*) [32,33]. Antibiotics, high-fat diet, stress, and air pollution have all been linked to dysbiosis, which has been shown to affect other body systems [17,34]. During COVID-19 infection, microbiota dysbiosis such as *Klebsiella oxytoca*, *Lactic Acid Bacteria*, and Tobacco mosaic virus were discovered [35]. In addition, a study found a link between the severity of COVID-19 infection and the prevalence of *Clostridium ramosum*, *Coprococcus*,

Clostridium hathewayi, *Faecalibacterium prausnitzii*, and *Alistipes onderdonkii* [36].

The present narrative review discusses the interaction between the healthy microbiome and the immune system during the initiation and progression of COVID-19. Finally, we overview the protective role of probiotics in the current COVID-19 pandemic.

2. Gut microbiota regulates the immune system

The number of microorganisms in the GI tract is reported to be more than 10^{14} . The total number of microbes encompasses about 10 times more than human cells [37]. Bacteria that inhabit the microbiota of the human gut are classified into phyla, classes, orders, families, genera, and species. Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Fusobacteria, and Verrucomicrobia are the significant gut microbial phyla [38,39]. Recent research has discovered that species and strains of microorganisms can control the host defense against different pathogens. According to the rodent studies, *Bacteroides fragilis* strain No. 9343 protects against colitis, while strain 86–5443-2-2 induces colitis [17,40]. *Clostridial* cluster IV and XIVa have also been shown to cause colonic Treg cells [41].

On the other hand, the density of DNA and RNA viruses that comprise the intestinal virome is equal to that of bacterial cells. At the same time, they may exceed bacterial cells by a 20:1 ratio on gut mucosal surfaces and within mucus layers [42]. Through inducing immune system tolerance, the gut virome maintains and develops diversity in the human gut microbiota in a dynamic equilibrium with the host. The regulation of human metabolism, inflammation, and carcinogenesis are all influenced by gut virome. Recent evidence showed that *Bacteriophages* play a role in human liver metabolism and immune response modulation [43]. Developing an immunoregulatory network that protects against induction of mucosal IgE, which is linked to allergy susceptibility, is also dependent on intestinal microbial diversity during early-life colonization [44].

The gut microbiota, including bacteria, archaea, and eukarya, colonize within the GI tract and co-evolve with the host over thousands of years to develop an intricate and mutually beneficial interaction. The gut microbiota influences the host immune system's induction, education, and function [45,46]. On the other hand, the immune system has largely evolved to maintain the host's symbiotic relationship with these diverse and evolving microorganisms. This immune system-microbiota alliance interweaves the innate and adaptive arms of immunity in a dialog that selects, calibrates, and terminates responses. This interaction also enables the maintenance of regulatory pathways to maintain tolerance to innocuous antigens [45–48]. Gut microbiota may modulate systemic immunity by regulating innate and adaptive immune homeostasis by developing metabolites and antimicrobial peptides against various pathogens [10,49,50]. Several studies showed a cross-talk between the gut microbiota and antigen-presenting cells (APCs) and neutrophil regulation, besides forming CD4 + T cells both within and outside the intestine [41,44,51–54]. A shift in the gut microbiota's composition can

have either a pathological or beneficial effects, mediated by the gut microbiota's regulation of specific CD4 + T cell subtypes [55]. Dysbiosis is linked to dysimmunity, commonly described as T-helper 2 (Th2)-overactivated and Treg-deficient state [19]. The gut microbiome's influence on the T cell compartment of the adaptive immune system is the best-understood mechanism by which the gut microbiota influences the systemic immunological response [46]. The GIT microbiota has been found to influence T cell development into Th1, Th2, and Th17 cells, as well as regulatory T cells [47]. It has been reported that *segmented filamentous bacteria* (SFBs) directly regulate the secretion of various antibacterial peptides leading to altered secretion of IL-17 by Th17 cells [56,57]. The number of Th17 cells in the lamina propria and the production of IgA in the intestinal mucosa were found to be reduced by SFBs [58,59].

In response to the microbiota signal, secretory IgA (sIgA), IL-12, IL-22, and IFN- α are secreted. sIgA regulates local immunity, viral infection colonization, and proliferation [60]. Short-chain fatty acids (SCFAs) are one of the common metabolites produced by the gut microbiota and rapidly absorbed by intestinal epithelial cells (IECs) [61]. SCFAs regulate immune cell bioactivity, such as glucose homeostasis, gene expression profile, anticancer activity, and inflammatory response. SCFAs can also serve as a source of energy for T cell differentiation (Th1, Th2, Th17, and T regulatory (Treg) cells). Interestingly, SCFAs can induce tolerance in dendritic cells (DCs) which contributes to the differentiation of naïve CD4 + T cells into Treg cells [62]. Common SCFAs include propionate (from *Bacteroidetes*), butyrate (from *Firmicutes*), and acetate (from most gut anaerobes) [60,63]. Butyrate enhances the differentiation of Treg cells and prevents the development of systemic inflammation [48]. The potential of microbiota-released signaling molecules to enter the circulation also enables resident bacteria in the gut to affect the immune system during immune cell formation in hematopoiesis, and hence alter infection response [64]. Moreover, the SCFA butyrate induces bone marrow monocyte differentiation from an inflammatory to a more tolerogenic phenotype [48]. A decrease in butyrate-producing bacteria and gut dysbiosis, in particular, resulted in reduced IL-22 production, which is necessary for gut and lung epithelial barrier integrity [65]. Acetate is the most abundant SCFA produced in high quantities by *Bifidobacteria*, and is found in the gut lumen and peripheral circulation [66]. Acetate modulates intestinal inflammation by activating G protein-coupled receptor 3 (GPR43) [67], thereby contributing to the maintenance of gut epithelial barrier function [68]. Acetate also has anti-inflammatory characteristics in neutrophils, decreasing NF- κ B activation by suppressing the levels of pro-inflammatory mediators such as lipopolysaccharide-induced TNF- α [66].

The mucus in the intestines and lungs is considered the first defense line against pathogen colonization [69]. The luminal layer of the gut mucosa is a suitable site for the colonization of commensal bacteria. Furthermore, the gut microbiota regulates the integrity of the mucosal barrier, provides bacterial metabolites [37,70], and regulates the immunoregulatory functions of IECs by modulating the expression of

antimicrobial factors [71,72]. As one of the critical bacterial metabolites, butyrate regulates transepithelial fluid transport, reduces mucosal inflammation and oxidative stress, improves the epithelial defense barrier, and controls visceral sensitivity and intestinal motility [73]. Moreover, butyrate provides a critical line of immunologic defense in the intestine *via* induction of DCs tolerance in the epithelium, which is associated with mucosal IgA production. Butyrate also suppresses mast cell degranulation in the intestinal mucosa and limits circulating inflammatory mediators' production [74]. So, the absence of the gut mucosa reduces the commensal bacteria adhesion and IECs integrity and result in direct contact with bacteria which eventually causes inflammation in the gut [75]. On the other hand, SCFAs induce the expression of pattern recognition receptors (PPRs) on DCs and macrophages, which regulate cytokine secretion and antibody synthesis (sIgA and IgM) [76].

The balanced production of antiviral cytokines is associated with specific GIT bacteria, including *Faecalibacterium*, *Oscillibacter*, *Pseudoflavonifractor*, *Anaerotruncus*, and *Bifidobacterium*. It has been reported that antibiotic administration in chickens resulted in higher susceptibility to the avian influenza virus (AIV) and reduced expression of IFN- α , IFN- β , and IL-22 levels [77]. The synthesis of microbial peptides in the gut is regulated by the key active components of innate immunity such as α -defensin (DEFA) and C-type lectins (REG3g and REG3b) [60]. Menendez *et al.* showed that germ-free mice had a significant decrease in the expression of DEFA [78]. Toll-like receptors (TLRs) and NOD-like receptors (NLRs) on DCs and macrophages help the immune system to distinguish between useful and pathogenic bacteria [79]. IECs also express these transmembrane receptors, which are involved in the recognition of different microbe-associated molecular patterns (MAMPs) *e.g.* peptidoglycan, capsular polysaccharides, lipopolysaccharides (LPS), and flagellin and bacterial DNA CpG motifs [80].

Gut-associated lymphoid tissue (GALT), composed of lamina propria, intraepithelial lymphocytes, mesenteric lymph nodes, Peyer patches, and isolated lymphoid follicles, helps defend against external factors that penetrate the luminal mechanical barrier [38]. Experimental evidence has established the role and function of gut microbiota in GALT regulation [81,82]. Accordingly, germ-free mice developed hypoplastic Peyer's patches/mesenteric lymph nodes in the small intestine, but no isolated lymphoid follicles (ILFs) [83]. The first colonization of gut microorganisms in full-term infants depends on GALT maturation and GI-Blood Barrier critical closure. These interactions result in the formation of symbiotic conditions, which are defined as a balance between immunity and infections [84].

During early life, critical host immune-microbiota interactions occur, which may have long-term effects on multiple immune arms that contribute to immune homeostasis and sensitivity to infectious and inflammatory diseases later. However, the mechanisms underlying these interactions are remaining unclear. In this regard, future studies are needed to determine the long-term effects of mild dysbiosis states during the neonatal period on adult immunity and the risk of immune-mediated diseases [44].

3. Gut microbiota–lung axis

A healthy lung contains 10–100 bacteria per 1,000 cells [85]. *Bacteroidetes*, *Firmicutes*, and *Proteobacteria* are the most common phyla colonizing the healthy lung [86]. There is a constant cross-talk between the gut and lung mucosal compartments through the mesenteric lymphatic system and lung lymph nodes. Physical interaction, quorum-sensing molecules, and synthesis of antimicrobial agents could all be involved in these interactions, which could modulate the lung's immune response [87]. Changes in the microbial composition of the lung can influence the community of gut microbiota and *vice versa*. Due to possible barrier dysfunction, bacterial translocation from the gut to the lungs has been documented in sepsis and acute respiratory distress syndrome

[88]. The gut and respiratory tract have been linked to control immunological responses, and dysbiosis in the gut microbiota leads to development of respiratory disease [89]. Mechanisms involved in microbiota–lung–gut-axis alteration in COVID-19 include direct lung damage, ACE2 expression, gut microbiota as lungs' defense against SARS-CoV-2, and immune response [90]. In 2012, researchers demonstrated that colonization of the influenza virus in the respiratory tract of mice causes intestinal dysbiosis by increasing *Enterobacteriaceae*, while reducing *Lactobacilli* and *Lactococci* [91]. In consistent with these findings, IBD and IBS patients with many lung disorders, including asthma, chronic obstructive pulmonary disease (COPD), influenza virus, and coronavirus, exhibited dysbiosis in their airway microbiota [92–94]. As illustrated in Figure 1, Figure 2 the commensal intestinal microbiota plays an




Figure 1. The gut–lung axis plays a critical role in the control of SARS-CoV-2 virulence. The gut microbiota regulates the innate and adaptive immunity by producing bacterial metabolites (SCFAs) and antimicrobial peptides against different pathogens. In addition, they regulate the integrity of the mucosal barrier and immune homeostasis. Dysbiosis can make negative impact on the balance and recruitment of immune cells in the lungs and increase inflammatory cytokines such as IL-6, TNF- α , and IL-1 β , which could be the most important predisposing factor for severe COVID-19 infection.




Figure 2. The interaction between the SARS-CoV-2 spike protein and ACE2 on the DCs and MQs contributes to the pathogenicity of COVID-19. Most critically ill patients in ICU, who are suffering from ARDS, have high levels of inflammatory cytokines owing to the complex immune dysregulation. Thus, the NABs can potentially block the interaction between the SARS-CoV-2 spike protein and ACE2 on the cell membrane and thus prevent the entry of the virus and can control viral load. There are supporting evidence suggesting that probiotics affect pulmonary health through gut-lung cross-talk. MAMPs are the microbiota-derived products/metabolites, such as SCFAs that have increased cellular levels of acetyl-CoA, ATP, and lipid biogenesis to drive plasma B cell's differentiation and induce IgAs and NABs secretion against viral respiratory infections particularly SARS-CoV-2 and modulate immune reactions.

essential role in regulating the immune response against respiratory virus infections such as influenza and coronavirus [8,95].

Moreover, alterations of the lung microbiota following infection can cause intestinal complications. Accordingly, *P. aeruginosa* pneumonia can reduce IECs proliferation and improve mucosal repair [96,97]. According to a meta-analysis, GI symptoms such as nausea, vomiting, diarrhea, and abdominal pain were seen in 17.6% of SARS-CoV-2 infected patients, and they were more common in severe cases [5]. These GI signs could be caused by SARS-CoV-2 directly infecting enterocytes through the GLA, or by immunoregulatory mechanisms [98]. On the other hand, dysbiosis in the gut microbiota negatively impacts on the balance and recruitment of immune cells in the lungs, which could be the most important predisposing factor in the development of respiratory tract infections [99]. In addition, this immune cell imbalance in the lungs reduces a load of certain beneficial bacteria (*Bifidobacteria*, *Akkermansia*, *Faecalibacterium*, *Lachnospira*, and *Veillonella*), which has been linked to an increased risk of asthma in neonates [100,101]. Table 1 summarizes the association between chronic respiratory diseases and changes in the microbial composition of the gut or respiratory tract.

Metabolites of gut bacteria can reach other organs *via* the bloodstream and regulate immune responses at distal mucosal sites such as the lungs. This control can be seen in the induction of antibody synthesis and anti-inflammatory responses [99,124]. Microbiota and viruses interact in both direct and indirect ways [125]. Microbiota-produced

lipopolysaccharides (LPS) and peptidoglycans compete with viruses to bind to cell surface receptors, such as TLRs. COVID-19 infection symptoms are found to be more severe in the absence of LPS. TLR4 is one of the leading players of the immune system against COVID-19 infection. Indirectly, microbiota can regulate the secretion of IFN- α and antimicrobial peptides, which are essential in preventing virus-host cell fusion. Therefore, they can prevent viral colonization using the S protein [126–128]. According to the experimental studies in a mouse model, dysbiosis in the lung impacts the immune system, reducing the recruitment of APCs to the lungs and phagocytic activity. In addition, less intensive recruitment of immune cells results in an increase in viral load in the lungs [129,130] and a decrease in IFN- α and - β production which can negatively impact T cell priming [130]. It was shown that active resident memory B cells in the lungs also required encountering lung microbiota [131]. This interaction is reciprocal, and any changes in the gut microbiota directly affect the host's defense against acute respiratory pathogens as well as the risk of death [87].

4. Gut microbiota and immune system in COVID-19

Changes in the gut microbiota increase the risk of infectious, inflammatory, and endocrine diseases. Since there is no approved treatment or vaccine for many respiratory viral infections [132], a healthy immune system can play a key role in reducing the severity of symptoms and mortality. SARS-CoV belongs to the subfamily of Orthocoronavirinae in the family

Table 1. The association between respiratory chronic diseases and alterations of the intestinal and respiratory tract microbial composition.

Type of Disease/Infection	Alteration of gut bacteria		Subject	Reference
	Decreased	Increased		
Asthma (in children)	<i>Akkermansia muciniphila</i> , <i>Faecalibacterium prausnitzii</i>	<i>Clostridia</i>	Human	[102] [103]
Asthma (in adults)	<i>Bacteroidetes</i> (specifically), <i>Prevotella</i> spp.	<i>Proteobacteria</i> (<i>Haemophilus</i> , <i>Moraxella</i> , <i>Neisseria</i> spp.) <i>Firmicutes</i> (<i>Lactobacillus</i> spp.)	Human	[85,104]
Chronic Obstructive Pulmonary Disease (COPD)		<i>Enterobacter cloacae</i> , <i>Citrobacter</i> , <i>Eggerthella</i> , <i>Pseudomonas</i> , <i>Anaerococcus</i> , <i>Proteus</i> , <i>Clostridium difficile</i> , <i>Salmonella</i>	Human	[105]
Cystic fibrosis (in children)	<i>Bacteroides vulgatus</i> <i>Bacteroides uniformis</i> <i>Firmicutes</i> <i>Faecalibacterium prausnitzii</i> , <i>Bifidobacterium adolescentis</i> <i>Bifidobacterium catenulatum</i> , <i>Eubacterium rectale</i>	<i>Streptococcus</i> , <i>Staphylococcus</i> , <i>Veillonella dispar</i> , <i>Clostridium difficile</i> , <i>Pseudomonas aeruginosa</i> , <i>Escherichia coli</i>	Human	[106]
Cystic fibrosis (in adults)	<i>Bacteroidetes</i> , <i>Faecalibacterium prausnitzii</i>	<i>Firmicutes</i> , <i>Ruminococcus gnavus</i> , <i>Enterobacteriaceae</i> , <i>Clostridia</i> species <i>Proteobacteria</i> phylum (<i>Pseudomonas</i> , <i>Haemophilus</i> , <i>Burkholderia</i>), <i>Actinobacteria</i> phylum	Human	[107–111]
Lung cancer	<i>Bifidobacterium</i> sp., <i>Actinobacteria</i> sp. <i>Dialister</i> , <i>Enterobacter</i> , <i>Escherichia–Shigella</i> , <i>Faecalibacterium</i> , and <i>Kluyvera</i>	<i>Enterococcus</i> sp. <i>Veillonella</i> , <i>Bacteroides</i> , <i>Fusobacterium</i>	Human	[112,124]
Type of Disease/Infection	Alteration of respiratory tract bacteria	Increased	Subject	Reference
Coronaviruses and Adenoviruses infection	Decreased	<i>M. catarrhalis</i>	Human	[113]
COPD and Rhinovirus infection		<i>Proteobacteria</i> phylum	Human	[130]
Rhinovirus infection		<i>H. parainfluenzae</i> , <i>Neisseria subflava</i> , <i>S. aureus</i>	Human	[114]
Rhinovirus infection (in children)		<i>S. pneumoniae</i>	Human	[115]
COPD and hRV infection		<i>H. influenza</i>	Human	[116]
hRV infection	<i>Haemophilus</i> and <i>Neisseria</i> spp.	<i>Propionibacterium</i> <i>S. pneumonia</i> <i>H. influenza</i> <i>S. pneumoniae</i>	Human	[113,117]
Enteroviruses		<i>Prevotella</i> , <i>Streptobacillus</i> , <i>Porphyromonas</i> , <i>Granulicatella</i> , <i>Veillonella</i> , <i>Fusobacterium</i> , <i>Haemophilus</i> .	Human	[113]
Influenza (in children)	<i>S. aureus</i>	<i>Firmicutes</i> (<i>Staphylococcus</i> and <i>Streptococcus</i> spp.), <i>Proteobacteria</i> (<i>Pseudomonas amygdali</i> , <i>P. fluorescens</i> , <i>Pseudomonas</i> sp. UK4, <i>Acinetobacter baumannii</i> and <i>A. junii</i>) <i>Moraxella</i> and <i>Enterobacter</i> spp.	Human	[118] [119]
Influenza A H1N1 infection		<i>Neisseria</i> <i>Haemophilus</i> and <i>Moraxella</i>	Human	[120] [120]
Haemophilus influenza infection			Human	[120]
Influenza, Parainfluenza, Rhinovirus, Respiratory Syncytial Virus (RSV), Coronavirus, Adenovirus, Metapneumovirus		<i>Prevotella</i> and <i>Flavobacterium</i>	Human	[120]
Pseudomonas aeruginosa infection			Human	[121]
H7N9 virus infection	<i>Faecalibacterium</i>	<i>H. influenzae</i>	Human	[113]
Respiratory Syncytial Virus (RSV)		<i>Roseburia</i> , <i>Faecalibacterium</i> , <i>Phascolarctobacterium</i> , <i>Eubacterium</i>	Human	[122]
Tuberculosis infection		<i>Proteobacteria</i> , <i>Actinobacteria</i>	Human	[123]
Recurrent tuberculosis	<i>Bacteroidetes</i> , <i>Prevotella</i> and <i>Lachnospira</i>			

of Coronaviridae. The enveloped and crown-like SARS-CoV virus is the second-largest genome size (27–32 kb) and single-strand positive-sense RNA (+ssRNA) of all RNA viruses (27–32 kb). Lv *et al.* reported an imbalance of fungal and bacterial flora in COVID-19 patients [133]. A study of the diverse array of fungal species, which refers to the diverse array of fungal species the gut mycobiota [134] showed that the most common symptom of fungal mycobiota dysbiosis in COVID-19-infected patients was the depletion of *Aspergillus* and *Penicillium*. Interestingly, the gut mycobiota profiles of COVID-19 patients with mild and severe symptoms were similar. In COVID-19 patients, the gut virome, especially in those with GI infections, can be very significant [135]. COVID-19 patients had significant differences in their fecal mycobiome at the time of hospitalization compared to controls, including

Candida albicans enrichment and a highly heterogeneous mycobiome composition that lasted up to 12 days after nasopharyngeal clearance of SARS-CoV-2, according to a recent report [136]. Fecal metabolomic analysis in COVID-19 patients has revealed possible amino acid-related pathways that relate gut microbiota to inflammation [137]. In patients with COVID-19, Zuo *et al.* studied the temporal transcriptional activity of SARS-CoV-2 and its relationship with longitudinal fecal microbiota modifications. They showed that SARS-CoV-2 RNA was found in 46.7% of stool samples of patients without GI symptoms. In fecal samples with high SARS-CoV-2 active viral transcription and replication *in vitro* (infectivity), the numbers of particular opportunistic pathogens, such as *Collinsella aerofaciens* and *Morganella morganii* spp. were higher than in fecal samples with low or no SARS-CoV-2 infectivity [138]. In a

previous investigation, qRT-PCR revealed that 14 of the 15 patients with COVID-19 (93%) tested positive for SARS-CoV-2 in fecal samples. By contrast, stool viral RNA metagenomics revealed that seven (47%) of them were positive for SARS-CoV-2 [136]. Fecal viral RNA metagenomics only detected positive samples with an abundance of $>3.2 \times 10^4$ copies per mL inoculum, as determined by qRT-PCR [138]. In COVID-19 patients with moderate fever, Zhou *et al.* evaluated the correlation between gut microbiota dysbiosis and abnormal immunological responses. Patients with fever had a significant different gut microbiota composition than those who did not have a fever. Patients with fever had higher opportunistic infections, including *Enterococcus faecalis* and *Saccharomyces cerevisiae* [139]. In the cross-sectional study conducted by Gu *et al.*, it was discovered that the microbiological profile of COVID-19 patients differed from that of patients with influenza A and healthy controls. They reported that COVID-19 patients had a lower microbial diversity, a higher concentration of opportunistic bacteria (Rothia, Streptococcus, Actinomyces, and Veillonella), and a lower proportion of beneficial microbes [140]. COVID-19 severity is thought to be caused by a cytokine storm [36], which is linked to the gut bacterial population. Several immunomodulatory gut commensals, including *Faecalibacterium prausnitzii*, *Eubacterium rectale*, and *bifidobacteria* were reduced in COVID-19 patients [141]. Moreover, butyrate-producing bacteria including *Faecalibacterium prausnitzii*, *Clostridium butyricum*, *Clostridium leptum*, and *Eubacterium* were found to be in lower abundance [142]. Beneficial commensals including *Eubacterium ventriosum*, *Faecalibacterium prausnitzii*, *Lachnospiraceae* taxa, *Roseburia*, and *Bacteriodes* spp. like *B. dorei*, *B. massiliensis*, *B. ovatus*, and *B. thetaiotaomicron*, as well as *Bacteriodes* spp. like *B. dorei*, *B. massiliensis*, *B. ovatus* were diminished in COVID-19 cases, which correlated with the severity of the disease [143]. The previous studies have indicated that microbiota-derived SCFAs play an important role in promoting beneficial IL-18 and IL-22 secretion [144]. Moreover, Proteobacteria regulate the strong natural antiviral activity of IFN- α secretion [145]. The major phyla in the healthy gut and lungs are *Bacteroidetes* and *Firmicutes*. According to Yasui *et al.* feeding *Lactobacillus casei* to BALB/c mouse pups before inoculation with influenza virus decreases viral titers in the nasal lavage fluid and increases the activity of pulmonary natural killer (NK) cells. They demonstrated that the survival rate was nearly tripled under this type of regime [146]. Nasal administration of *Lactobacillus rhamnosus* also induced protection against respiratory syncytial virus infection in mice [147]. The SARS-CoV entry by TLRs (TLR3 or TLR7) results in airway inflammation [76]. Similarly, oral administration of immunobiotic *L. rhamnosus* in BALB/c mice was found to modulate antiviral immunity in the respiratory system. Activation of TLR3 and NK cells stimulate DCs to produce IL-12 as a critical factor in the development of effector CD4 Th1 and cytotoxic TCD8 lymphocyte responses [148,149].

Through the immediate response of the innate immune system to the coronavirus infection, macrophages and DCs regulate the virulence and disease outcomes. Furthermore, macrophages and DCs upregulate IFN- α production [76,150].

Some studies have shown that SARS-CoV inhibits the production of IFN- α and IFN- β [76]. Cinatl *et al.* showed that SARS-CoV could suppress the secretion of IFN- α , IFN- β , IL-18, and macrophage inhibitory factor (MIF), and downregulate the expression of antiviral genes (MIF). In addition, SARS-CoV could upregulate chemoattractant cytokines (CXC chemokines), IL-8, and oligoadenylate synthetase 2 (OAS2) in two intestinal cell lines, Caco2 and CL-14 [151]. In another study, it has been demonstrated that SARS-CoV infection downregulates the expression of IFN- α , IFN- β , as well as NF- κ B, and also reduces the p56 level in Caco2 and 293 cell lines [152]. If the first line of immune response fails in eliminating the viral pathogens, the adaptive immune response is activated seven days following the SARS-CoV infection and this gap is a golden time for virus replication. The Angiotensin II converting enzyme (ACE2) is an essential receptor for infecting human cells by coronaviruses [153]. Fischer and colleagues have shown that gut microbiota and a healthy diet directly regulate the expression of ACE2 and the activation of the adaptive immune response following viral infection [154]. In this regard, the gut microbiota via its metabolite signals can regulate the immune response, reduce viral replication, and increase the survival rate during an epidemic and pandemic of viral infection [124].

5. Probiotics and a diet, modulation of severe complications in COVID-19

Although the evidence suggests that the gut contains a remarkable number of immune cells [155], the gut microbiome plays a crucial role in protecting the host against pathogens. Dysbiosis leads to break tolerance to harmless bacteria, inefficient immune response, and susceptibility to viral infections. Probiotics, known as beneficial live microorganisms, regulate dysbiosis and restore eubiosis [156]. Lactic acid bacteria (LAB) (*Lactobacillus* and *Bifidobacterium* spp) are the main probiotics species [157] that are well-known to the immune system and can regulate immune responses [158]. *Lactobacillus* spp acting via different pathways has antiviral features and could be considered a potent inducer of IFN- α and IFN- β production. Mullish *et al.* showed evidence for probiotics' possible effect in reducing viral upper respiratory tract infections (URTI) and maybe COVID-19, especially in overweight/obese adults. They discovered that probiotic supplementation could reduce URTI symptoms by 27%, with adults ≥ 45 years old and/or with a BMI ≥ 30 kg/m², obtaining the significant benefit of risk reduction [159]. In one early trial, probiotic supplementation to 28 hospitalized COVID-19 patients resulted in an eightfold decreased rate of respiratory failure compared to 42 patients receiving only medical treatment [160]. Probiotics treatment (*Bacillus subtilis*, *Enterococcus faecalis*, and *Lactobacillus rhamnosus* GG) was also found to lower ventilator dependency in COVID-19 patients who were severely ill compared to placebo. The mechanisms of probiotics' antiviral effects are still unclear [98]. Prebiotics are substrates that host certain microorganisms and are used to provide a health benefit such as fructans, galactomannan, oligosaccharides, arabinooligosaccharides, lactosucrose, acid

lactobionic, and polyunsaturated fatty acids [161]. Prebiotics can modulate the composition and function of the human microbiota, inducing immune system activation and pathogen inhibition in the GIT. To date, however, there is no evidence that prebiotics are associated with COVID-19 infections in any way [162].

Fecal microbiota *L. gasseri* SBT2055 (LG2055) is resistant to bile acid and can be colonized in the human gut [163]. The most current data support the regulatory role of LG2055 in the IgA secretion, which inhibits the influenza A virus infection in mice [164–166]. Eguchi and colleagues showed the antiviral activity of *L. gasseri* SBT2055 in both *in vivo* and *in vitro* models. These bacteria reduced viral load in the lungs and suppressed pro-inflammatory cytokine production [167]. Recently, it has been demonstrated that the cell walls of *L. acidophilus* NCFM and live *Lactobacillus* spp enhanced the immune system's response to viral respiratory infection. Heat-killed *L. casei* [168], *L. pentosus* [169], *L. plantarum* [170], *L. reuteri* [170], and *L. rhamnosus* CRL1505 [171] participated in the regulation of the immune response in the respiratory tract and reduced lung damage after influenza and respiratory syncytial virus infections (RSV). The direct competition in binding to TLR3 between viral particles and local bacteria present in the lung resulted in decreased virus colonization in mice [172]. *Bifidobacterium*, the other group of LAB, regulates lung inflammation and infection. Supplementation with *B. breve* and *B. longum* (BL) improved the survival rate, restored lung injury, and eventually restored intestinal homeostasis [173–175]. Treatment with a *Bifidobacterium* probiotic can modulate pro-inflammatory cytokine levels and increase IL-10 and Foxp3⁺ Treg expression in the lungs. Animal studies have demonstrated that oral administration of *B. longum* BB536 reduces the incidence of influenza and fever, and can also regulate proliferation of the influenza virus in the lungs [176].

In comparison with oral treatment, nasal administration of *L. rhamnosus* CRL1505 tends to be a more effective way to significantly activate the Th1 response and CD103⁺c DCs [177]. Likewise, the nasal administration of *Lactobacillus* leads to faster colonization on the respiratory epithelium than oral way. The nasal administration is highly effective in suppressing the virus-induced inflammation and also diminishes the expression of inflammatory cytokines and chemokines (CXCL10, CXCL1, CCL2, TNF, IL-6) that damage lung tissue [170]. The effects of probiotics on the regulation of the immune system in infectious respiratory diseases have been summarized in Table 2.

Absorptive trapping and the development of lipopolysaccharides, which binds to and destabilizes the viral structure, are two mechanisms by which gut commensal bacteria (including those often found in probiotics) suppress viruses that enter the host *via* the upper respiratory tract [186]. The gut-lymph hypothesis, which describes gut bacteria within the draining chyle from the lower GIT entering the lymphatic system, is also one possible route by which probiotic bacteria may translocate from the gut to the lung [187]. Additional indirect pathways include modulating interferon responses in the lung stromal cells [188], promotion of APCs migration, and T cell antiviral responses mediated by TLRs [129].

Modifying nutrient availability *via* diet may be another effective microbiome-modulating strategy. A healthy diet is even more critical due to its effect on the microbial metabolome and richness of the microbiota diversity [189]. Therefore, alteration of the gut microbiota can increase the production of SCFAs *via* diet modification. Interestingly, adding indigestible carbohydrates increased butyrate production, which is linked to improved lung function. Also, fiber-rich diets can modulate innate immunity and reduce the GI signs and mortality rate from respiratory diseases [190,191]. Collectively, probiotics and

Table 2. The effects of probiotics on the immune system regulation in infectious respiratory diseases.

Probiotic	Efficacy	Subjects	Administration Route	Reference
<i>L. acidophilus</i>	Induced secretion of IFN- α , IFN- β , and IL-12 from DCs via TLR2 and TLR-3	Mice	Oral	[146]
<i>L. rhamnosus</i> CRL1506	Production of IFN- α and IL-6	Mice	Oral	[51]
<i>L. casei</i> Shirota (LcS)	Activated Th1 immunity, phagocytic activity, NK cells activity, and production of mucosal IgA	Mice/Elderly people	Oral/ Intranasal	[178,179]
<i>L. delbrueckii</i> ssp. <i>bulgaricus</i> OLL1073R-1	Increased NK cells activity	Elderly people	Oral	[168]
<i>L. gasseri</i> SBT2055 (LG2055)	Induced IFN- α & IFN- β production	Mice	Oral	[150]
Heat-killed <i>Lactobacillus plantarum</i> L-137	Increased phagocytic activity and NK cells activity, acquired immunity, proliferative response of T cells, and increased number of T cells	mice/ Healthy adults	Oral	[181,182]
Heat-killed <i>L. pentosus</i>	Modulation of Th1/Th2, enhanced NK cells activity, induced production of both IL-12 and IL-10	Mice	Oral	[169]
Heat-killed <i>L. plantarum</i>	Stimulation of IFN- β and IL-10 production	Mice	Intranasal	[170]
<i>L. reuteri</i>	Stimulation of IFN- α production	Mice	Nasal	[171]
<i>L. rhamnosus</i> CRL1505	Th1 response significantly activated CD103 ⁺ c DCs	Mice	Oral	[154]
<i>L. Casei</i> Shirota (LcS)	Activation of Th1 immunity	Mice	Intranasal	[168]
<i>L. fermentum</i>	Activation of macrophages	Mice	Intranasal	[113]
<i>L. pentosus</i> S-PT84	Enhanced splenic NK cells, modulating the Th1/Th2 balance	Mice	Intranasal	[183]
<i>L. johnsonii</i>	Reduction in the total number and proportion of activated CD11c ⁺ /CD11b ⁺ CD11c ⁺ /CD8 ⁺ cells, reduced expression of airway Th2 cytokine	Mice	Intranasal	[184]
<i>B. breve</i> YIT4064	Enhanced IgG against IFV	Mice	Oral	[185]
<i>B. longum</i> BB536	Reduced the incidence of IFV and fever effect on host cellular immunity, enhanced production of Th1 cytokines, declined plasma IFN- γ levels, enhanced NK cell activity and neutrophil bactericidal activity.	Mice	Oral	[171]
<i>B. longum</i> MM-2	Anti-viral effect, enhanced activity of NK cells in the lungs and spleen, Increased expression of IFN- α and Th1-related cytokines,	Mice/healthy adults	Oral	[171]

Mediterranean lifestyle are protective, increase survival rate, and protect lung tissue against the destructive effects of respiratory viruses (SARS-CoV2, IFV, RSV, etc.) and could be considered an alternative therapy for improving immune response.

6. Fecal microbiota transplantation in COVID-19 patients

Fecal microbiota transplantation (FMT) is a novel treatment that has shown to be helpful in the treatment of recurrent *Clostridioides difficile* infections (rCDI). FMT has the potential to help with a variety of dysbiosis-related disorders. It refers to transferring a healthy person's distal gut microbiota communities to another patient's intestinal tract. This treatment has been proven to restore a disrupted microbial diversity and related microbial functional networks, with a success rate of 90% for rCDI patients [192]. According to Bradley *et al.*, decreased intestinal microbiota following antibiotic administration could cause a shift in the interferon signature triggered by commensals in the lung epithelium, promoting early influenza virus proliferation in the respiratory tract [188]. By monitoring COVID-19 patients, Liu *et al.* revealed persistent alteration in the fecal microbiome composition after recovery and discharge from hospital [193]. They reported that *Firmicutes*, *Bacteroidetes*, *Actinobacteria*, and *Proteobacteria* had relative abundances of 41.0%, 42.9%, 9.2%, and 4.0%, respectively, which differed from the general population. In healthy people, the dominant phyla are *Firmicutes* (60%) and *Bacteroidetes* (20%) [194]. Multiple research has shown that the FMT can promote immune function and consequently have an indirect protective effect against influenza virus infection [188]. Tiffany *et al.*, used FMT on rhesus monkeys infected with chronic SIV who were receiving antiretroviral medication. After antibiotic therapy, microbiota shift was observed, whereas Th17 and Th22 frequencies in peripheral blood increased and CD4 T cell activation in the intestinal tract reduced following FMT [195]. Liu *et al.* investigated the effects of FMT on GI symptoms, gut dysbiosis, and immune status in 11 discharged COVID-19 patients. After FMT, the COVID-19's peripheral lymphocyte subset was altered. The gut microbiota was restored, and GI disorders were relieved, suggesting that FMT could be used as a therapeutic and rehabilitative intervention [193]. Further research is needed to understand whether FMT could be a viable technique for altering the gut microbiome to improve COVID-19's residual effect.

7. Conclusion

The link between human microbiota and COVID-19 is still unknown. This narrative review aimed to assess and summarize available evidence on the relationship between the microbiome and COVID-19 in patients in the pandemic era. The current study uncovered several major issues that call for more investigation on microbiota in COVID-19 patients. There is a crucial cross-talk between the gut microbiota and the lungs through the GLA. The protection of the gut microbiota hemostasis, especially in the absence of treatment for a viral respiratory infection, could be more practicable to

regulate the immune system response and reduce the GI disorder after COVID-19 infection. Healthy gut microbiota might lead to asymptomatic or mild COVID-19 infection without any severe clinical complications. Probiotics have been shown to modulate the occurrence and severity of diseases, implying that they may be used to treat or prevent COVID-19. By preserving the human GI or lung, probiotics could help prevent COVID-19. More than ever, this pandemic has highlighted the importance of the gut microbial–host–immune axis and the impact of the fecal metabolome on inflammation control and regulation of the immune system. To investigate the possible preventive and therapeutic effects of probiotics against SARS-CoV-2 infection, *in vitro* and clinical studies are necessary.

8. Expert opinion

During hospitalization, gut microbiota composition may influence the immune response and change the severity and prognosis of COVID-19 [196]. Thus, a microbiome-oriented risk-assessment profile could be used to identify those at risk [197]. Additionally, since the human microbiome is adaptive and may be changed through dietary modifications [198], we believe that further research is urgently needed to assess the impact of microbiota and diet on COVID-19 [198]. However, the detection of enriched inflammatory-associated gut microorganisms in COVID-19 is controversial. The question is if they enriched or this was happened due to the reduction of the other microorganisms. It seems that longer follow-up is needed for COVID-19 patients, such as three months to 1 year after virus clearance. This will enable us to find a correlation of gut microbiota composition to long-term persisting symptoms. In addition, this can assess the possible alteration of the gut microbiota dysbiosis post-recovery. Also, it can help to determine whether enrichment or depletion of specific gut microorganisms can contribute to future health problems [141].

On the other hand, the described gut dysbiosis may just be a response to patients' health and defensive statuses rather than playing a central role in disease severity. Accordingly, it is not clear how much clinical practice during hospitalization can affect the gut microbiota composition in COVID-19 patients. Of note, it is anticipated that 50% to 75% of COVID-19 patients received antibiotics, while just about 7% of them displayed bacterial infections [199]. Moreover, according to Chinese studies, antibiotics were given to 58.71% of COVID-19 patients, while 2–36% suffering from diarrhea. Even though probiotics have only a little efficacy in treating antibiotic-induced diarrhea, the use of probiotics has been indicated to reduce susceptibility to recurrent infection [98]. Previously, it has been found that polypharmacy significantly impacts microbiota composition and that more alterations could be observed if the number of co-administered drugs increases [200].

In conclusion, the implication of sufficient, safe, and cost-benefit pre- and probiotics can support the microbiota. Their prescription can be used as an adjuvant therapy to modulate COVID-19 progression or as a preventive strategy for non-

infected individuals who are at risk during the COVID-19 pandemic.

Funding

This paper was not funded.

Declaration of interests

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.

References

Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.

- Mathew S, Smatti MK, Al Ansari K, et al. Mixed viral-bacterial infections and their effects on gut microbiota and clinical illnesses in children. *Sci Rep*. 2019;9(1):865.
- Hanada S, Pirzadeh M, Carver KY, et al. Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. *Front Immunol*. 2018;9:2640.
- Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. *Glob Health Res Policy*. 2020;5:6.
- Cully M. Immune status could determine efficacy of COVID-19 therapies. *Nat Rev Drug Discov*. 2020;19(7):431–434.
- Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. *Gastroenterology*. 2020;159(1):81–95.
- El Moheb M, Naar L, Christensen MA, et al. Gastrointestinal complications in critically ill patients with and without COVID-19. *JAMA*. 2020;324(18):1899–901.
- Kaafarani HM, El Moheb M, Hwabjire JO, et al. Gastrointestinal complications in critically ill patients with COVID-19. *Ann Surg*. 2020;272(2):e61.
- Budden KF, Gellatly SL, Wood DLA, et al. Emerging pathogenic links between microbiota and the gut–lung axis. *Nature Rev Microbiol*. 2017;15(1):55.
- Hugon P, Dufour J-C, Colson P, et al. A comprehensive repertoire of prokaryotic species identified in human beings. *Lancet Infect Dis*. 2015;15(10):1211–19.
- Cianci R, Pagliari D, Piccirillo CA, et al. The microbiota and immune system crosstalk in health and disease. *Mediators of Inflammation*. 2018;2018:1–3.
- Zhu G, Jiang Y, Yao Y, et al. Ovotransferrin ameliorates the dysbiosis of immunomodulatory function and intestinal microbiota induced by cyclophosphamide. *Food Funct*. 2019;10(2):1109–1122.
- Xie Q, Pan M, Huang R, et al. Modulation of the small intestinal microbial community composition over short-term or long-term administration with *Lactobacillus plantarum* ZDY2013. *J Dairy Sci*. 2016;99(9):6913–21.
- Belizário JE, Faintuch J. Microbiome and gut dysbiosis. *Exp Suppl*. 2018;109:459–476.
- Round JL, Mazmanian SKJNRI. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol*. 2009;9(5):313–23.
- Kamada N, Seo S-U, Chen GY, et al. Role of the gut microbiota in immunity and inflammatory disease. *Nat Rev Immunol*. 2013;13(5):321–35.
- Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and health. *Nat Clin Pract Gastroenterol Hepatol*. 2012;9(10):577.
- Mazmanian SK, Round JL, Kasper DLJN. A microbial symbiosis factor prevents intestinal inflammatory disease. *Nature*. 2008;453(7195):620–5.
- Gérard PJP. Metabolism of cholesterol and bile acids by the gut microbiota. *Pathogens*. 2014;3(1):14–24.
- Mezouar S, Chantran Y, Michel J, et al. Microbiome and the immune system: from a healthy steady-state to allergy associated disruption. *Hum Microbiome J*. 2018;10:11–20.
- Fleck A-K, Schuppan D, Wiendl H, et al. Gut–CNS-axis as possibility to modulate inflammatory disease activity—Implications for multiple sclerosis. *Int J Mol Sci*. 2017;18(7):1526.
- Wiest R, Albillos A, and Trauner, M et al. Targeting the gut–liver axis in liver disease. *J Hepatol*. 2017;67(5):1084–1103.
- Yurkovetskiy L, Burrows M, Khan A, et al. Gender bias in autoimmunity is influenced by microbiota. *Immunity*. 2013;39(2):400–412.
- Salem I, Ramser, A, and Isham, N, et al. The gut microbiome as a major regulator of the gut–skin axis *Front Microbiol*. 2018;9:1459.
- Sencio V, Barthelemy A, Tavares LP, et al. Gut dysbiosis during influenza contributes to pulmonary pneumococcal superinfection through altered short-chain fatty acid production. *Cell Rep*. 2020;30(9):2934–2947.
- Schuijt TJ, Lankelma JM, Scicluna BP, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. *Gut*. 2016;65(4):575–83.
- Keely S, Talley NJ, Hansbro PMJMI. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. *Mucosal Immunol*. 2012;5(1):7–18.
- Yazar A, Atis S, Konca K, et al. Respiratory symptoms and pulmonary functional changes in patients with irritable bowel syndrome. *Am J Gastroenterol*. 2001;96(5):1511–1516.
- Lotz MT, Peebles RS. Mechanisms of respiratory syncytial virus modulation of airway immune responses. *Curr Allergy Asthma Rep*. 2012;12(5):380–387.
- Brodin P, Davis MM. Human immune system variation. *Nat Rev Immunol*. 2017;17(1):21.
- Odamaki T, Kato K, Sugahara H, et al. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. *BMC Microbiol*. 2016;16(1):1–12.
- Fouhy F, Ross RP, Fitzgerald GF, et al. Composition of the early intestinal microbiota: knowledge, knowledge gaps and the use of high-throughput sequencing to address these gaps. *Gut Microbes*. 2012;3(3):203–220.
- Levine KM, Priedigkeit N, Basudan A, et al. FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. *NPJ Breast Cancer*. 2019;5(1):1–5.
- Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. *Genome Med*. 2016;8:51.
- Russell SL, Gold MJ, Reynolds LA, et al. Perinatal antibiotic-induced shifts in gut microbiota have differential effects on inflammatory lung diseases. *J Allergy Clin Immunol*. 2015;135(1):100–9. e5.
- Han Y, Jia, Z, and Shi, J, et al. The active lung microbiota landscape of COVID-19 patients. *medRxiv*, 2020.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054–1062.
- Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem J*. 2017;474(11):1823–1836.
- Scarpellini E, Fagoonee S, Rinninella E, et al. Gut microbiota and liver interaction through immune system cross-talk: a comprehensive review at the time of the SARS-COV-2 pandemic. *J Clin Med*. 2020;9(8):2488.
- Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. *Microorganisms*. 2019;7(1):14.
- Rabizadeh S, Rhee K-J, Wu S, et al. Enterotoxigenic *Bacteroides fragilis*: a potential instigator of colitis. *Inflamm Bowel Dis*. 2007;13(12):1475–1483.
- Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous *Clostridium* species. *Science*. 2011;331(6015):337–341.
- Mukhopadhyay I, Segal, JP, and Carding, SR, et al. The gut virome: the ‘missing link’ between gut bacteria and host immunity? *Therap Adv Gastroenterol*. 2019;12:1756284819836620.

43. Scarpellini E, Ianaro G, Attili F, et al. The human gut microbiota and virome: potential therapeutic implications. *Digestive Liver Dis.* **2015**;47(12):1007–1012.
44. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. *Cell Res.* **2020**;30(6):492–506.
45. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell.* **2014**;157(1):121–141.
46. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. *Nature.* **2016**;535(7610):75–84.
47. Owaga E, Hsieh R-H, Mugendi B, et al. Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases. *Int J Mol Sci.* **2015**;16(9):20841–20858.
48. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature.* **2013**;504(7480):451–455.
49. Cheng H-Y, Ning, MX, and Chen, DK, et al. Interactions between the gut microbiota and the host innate immune response against pathogens. *Front Immunol.* **2019**;10. DOI:10.3389/fimmu.2019.00607.
50. Pagliari D, Piccirillo CA, Larbi A, et al. The interactions between innate immunity and microbiota in gastrointestinal diseases. *J Immunol Res.* **2015**;2015:1–3.
51. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell.* **2009**;139(3):485–498.
52. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science.* **2012**;336(6086):1268–1273.
53. Gaudino SJ, Kumar P. Cross-Talk between antigen presenting cells and T cells impacts intestinal homeostasis, bacterial infections, and tumorigenesis. *Front Immunol.* **2019**;10:360.
54. Bene K, Varga Z, Petrov VO, et al. Gut microbiota species can provoke both inflammatory and tolerogenic immune responses in human dendritic cells mediated by retinoic acid receptor alpha ligation. *Front Immunol.* **2017**;8:427.
55. Wu H-J, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes.* **2012**;3(1):4–14.
56. Flannigan KL, Denning TL. Segmented filamentous bacteria-induced immune responses: a balancing act between host protection and autoimmunity. *Immunology.* **2018**;154(4):537–546.
57. Lécuyer E, Rakotobe S, Lengliné-Garnier H, et al. Segmented filamentous bacterium uses secondary and tertiary lymphoid tissues to induce gut IgA and specific T helper 17 cell responses. *Immunity.* **2014**;40(4):608–620.
58. Salzman NHJG. m., Paneth cell defensins and the regulation of the microbiome: detente at mucosal surfaces. *Gut Microbes.* **2010**;1(6):401–406.
59. Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. *Immunity.* **2009**;31(4):677–689.
60. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. *Environ Microbiol.* **2017**;19(1):29–41.
61. Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. *Front Endocrinol (Lausanne).* **2020**;11:25.
62. Corrêa-Oliveira R, Fachi JL, Vieira A, et al. Regulation of immune cell function by short-chain fatty acids. *Clin Transl Immunology.* **2016**;5(4):e73.
63. Rosshart SP, Vassallo BG, Angeletti D, et al. Wild mouse gut microbiota promotes host fitness and improves disease resistance. *Cell.* **2017**;171(5):1015–1028.
64. Khosravi A, Yáñez, A, and Price, JG, et al. Gut microbiota promote hematopoiesis to control bacterial infection. *Cell Host Microbe.* **2014**;15(3):374–381.
65. Lo BC, Shin, SB, and Canals Hernaez, D, et al. IL-22 preserves gut epithelial integrity and promotes disease remission during chronic *Salmonella* infection. *J Immunol.* **2019**;202(3):956–965.
66. Chen GY, Liu, M, and Wang, F, et al. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. *J Immunol.* **2011**;186(12):7187–7194.
67. Lukasova M, Malaval, C, and Gille, A, et al. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. *J Clin Investig.* **2011**;121(3):1163–1173.
68. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature.* **2009**;461(7268):1282–1286.
69. Gustafsson JK, Ermund A, Johansson MEV, et al. An ex vivo method for studying mucus formation, properties, and thickness in human colonic biopsies and mouse small and large intestinal explants. *Am J Physiol Gastrointest Liver Physiol.* **2012**;302(4):G430–8.
70. Jung T-H, Park JH, Jeon W-M, et al. Butyrate modulates bacterial adherence on LS174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway. *Nutr Res Pract.* **2015**;9(4):343–349.
71. Diamond G, Beckloff N, Weinberg A, et al. The roles of antimicrobial peptides in innate host defense. *Curr Pharm Des.* **2009**;15(21):2377–2392.
72. Kim D, Zeng MY, Núñez G, et al. The interplay between host immune cells and gut microbiota in chronic inflammatory diseases. *Exp Mol Med.* **2017**;49(5):e339.
73. Canani RB, Costanzo, MD, and Leone L, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. *World J Gastroenterol.* **2011**;17(12):1519–1528.
74. Salvi PS, Cowles RA. Butyrate and the intestinal epithelium: modulation of proliferation and inflammation in homeostasis and disease. *Cells.* **2021**;10(7):1775.
75. Jimenez JA, Uwiera, TC, and Abbott, DW, et al. Butyrate supplementation at high concentrations alters enteric bacterial communities and reduces intestinal inflammation in mice infected with *Citrobacter rodentium*. *MSphere.* **2017**;2(4):e00243–17.
76. Frieman M, Heise M, Baric RJVR. SARS coronavirus and innate immunity. *Virus Res.* **2008**;133(1):101–12.
77. Yitbarek A, Taha-Abdelaziz, K, and Hodgins, DC, et al. Gut microbiota-mediated protection against influenza virus subtype H9N2 in chickens is associated with modulation of the innate responses. *Sci Rep.* **2018**;8(1):1–12.
78. Menendez A, Willing, BP, and Montero, M, et al. Bacterial stimulation of the TLR-MyD88 pathway modulates the homeostatic expression of ileal Paneth cell α -defensins. *J Innate Immun.* **2013**;5(1):39–49.
79. Cianci R, et al. Tissue infiltrating lymphocytes: the role of cytokines in their growth and differentiation. *J Biol Regul Homeostat Agents.* **2010**;24(3):239.
80. Francino MPJP. Early development of the gut microbiota and immune health. *Pathogens.* **2014**;3(3):769–790.
81. Arrazuria R, Pérez V, Molina E, et al. Diet induced changes in the microbiota and cell composition of rabbit gut associated lymphoid tissue (GALT). *Sci Rep.* **2018**;8(1):14103.
82. Ahluwalia B, Magnusson MK, Öhman L. Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad. *Scand J Gastroenterol.* **2017**;52(11):1185–1193.
83. Fagarasan S, Muramatsu M, Suzuki K, et al. Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. *Science.* **2002**;298(5597):1424–1427.
84. Kasarello K, Sajdel-Sulkowska EM. Developmental significance of early gut-associated lymphoid tissue (GALT)-microbiota interactions in health and disease: creating balance between tolerance and inflammation in children. *Open J Pediatr Child Health.* **2019**;4(1):040–6. doi:10.17352/ojpch.000019.
85. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* **2012**;185(10):1073–1080.
86. Marsland BJ, Trompette A, Gollwitzer ESJAOTATS. The gut–lung axis in respiratory disease. *Ann Am Thorac Soc.* **2015**;12(Supplement 2):S150–S156.
87. Enaud R, Prevel R, Ciarlo E, et al. The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks. *Front Cell Infect Microbiol.* **2020**;10:9.

88. Dickson RP, Singer BH, Newstead MW, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. *Nat Microbiol.* **2016**;1(10):1–9.
89. Fanos V, Pintus MC, and Pintus, R, et al. Lung microbiota in the acute respiratory disease: from coronavirus to metabolomics. *J Pediatr Neonatal Individ Med(JPNIM).* **2020**;9(1): e090139
90. Battaglini D, Robba C, Fedele A, et al. The role of dysbiosis in critically ill patients with COVID-19 and acute respiratory distress syndrome. *Front Med.* **2021**;8:826.
91. Looft T, Allen HKJGM. Collateral effects of antibiotics on mammalian gut microbiomes. *Gut Microbes.* **2012**;3(5):463–467.
92. Fujimura KE, Lynch SVJCH. Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. *Cell Host Microbe.* **2015**;17(5):592–602.
93. Young RP, Hopkins RJ, Marsland B, et al. The gut–liver–lung axis. Modulation of the innate immune response and its possible role in chronic obstructive pulmonary disease. *Am J Resp Cell Mol Biol.* **2016**;54(2):161–169.
94. Baradaran Ghavami SH, Sharokh, SH, and Hossein-Khannazer, N, et al. IBD patients could be silent carriers for novel coronavirus and less prone to its severe adverse events: true or false? *Cell J.* **2020**;22 (Suppl 1):151–4.
95. Denny JE, Powell WL, Schmidt NW, et al. Local and long-distance calling: conversations between the gut microbiota and intra- and extra-gastrointestinal tract infections. *Front Cell Infect Microbiol.* **2016**;6:41.
96. Coopersmith CM, Stromberg PE, Davis CG, et al. Sepsis from *Pseudomonas aeruginosa* pneumonia decreases intestinal proliferation and induces gut epithelial cell cycle arrest. *Crit Care Med.* **2003**;31(6):1630–1637.
97. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *JAMA.* **2020**;323(11):1061–1069.
98. Rajput S, Paliwal, D, and Naithani, M, et al. COVID-19 and gut microbiota: a potential connection. *Indian J Clin Biochem.* **2021**;36(3) ;1–12.
99. Anand S, Mande SS. Diet, microbiota and gut-lung connection. *Front Microbiol.* **2018**;9:2147.
100. Arrieta M-C, Stiemsma LT, Dimitriu PA, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci Transl Med.* **2015**;7(307):307ra152.
101. Lynch S, Sitarik, AR, and Havstad, S, et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation *Nat Med.* **2016**;22(10):1187–1191 .
102. Demirci M, Tokman HB, Uysal HK, et al. Reduced *Akkermansia muciniphila* and *Faecalibacterium prausnitzii* levels in the gut microbiota of children with allergic asthma. *Allergol Immunopathol (Madr).* **2019**;47(4):365–371.
103. Kalliomäki M, Kirjavainen P, Eerola E, et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. *J Allergy Clin Immunol.* **2001**;107(1):129–134.
104. Hilty M, Burke, C, and Pedro, H, et al. Disordered microbial communities in asthmatic airways. *PLoS One.* **2010**;5(1):e8578.
105. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. *Am J Respir Crit Care Med.* **2011**;184(8):957–963.
106. Antosca KM, Chernikova DA, Price CE, et al. Altered stool microbiota of infants with cystic fibrosis shows a reduction in genera associated with immune programming from birth. *J Bacteriol.* **2019**;201(16):e00274–19.
107. Burke DG, Fouhy, F, and Harrison, MJ, et al. The altered gut microbiota in adults with cystic fibrosis. *BMC Microbiol.* **2017**;17 (1):58.
108. Fouhy F, Ronan NJ, O'Sullivan O, et al. A pilot study demonstrating the altered gut microbiota functionality in stable adults with cystic fibrosis. *Sci Rep.* **2017**;7(1):1–12.
109. Debyser G, Mesuere B, Clement L, et al. Faecal proteomics: a tool to investigate dysbiosis and inflammation in patients with cystic fibrosis. *J Cyst Fibros.* **2016**;15(2):242–250.
110. Blainey PC, Milla, CE, and Cornfield, DN, et al. Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis. *Sci Transl Med.* **2012**;4(153):153ra130.
111. Kolak M, Karpai, F, and Monstein, H-J, et al. Molecular typing of the bacterial flora in sputum of cystic fibrosis patients. *Int J Med Microbiol.* **2003**;293(4):309–317.
112. Zhuang H, Cheng L, Wang Y, et al. Dysbiosis of the gut microbiome in lung cancer. *Front Cell Infect Microbiol.* **2019**;9:112.
113. Rosas-Salazar C, Shilts MH, Tovchigrechko A, et al. Differences in the nasopharyngeal microbiome during acute respiratory tract infection with human rhinovirus and respiratory syncytial virus in infancy. *J Infect Dis.* **2016**;214(12):1924–8.
114. Hofstra JJ, Matamoros, S, and van de Pol, MA, et al. Changes in microbiota during experimental human Rhinovirus infection. *BMC Infect Dis.* **2015**;15(1):1–9.
115. Karppinen S, Teräsjärvi, J, and Auranen, K, et al. Acquisition and transmission of *Streptococcus pneumoniae* are facilitated during rhinovirus infection in families with children. *Am J Respir Crit Care Med.* **2017**;196(9):1172–1180.
116. Molyneux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* **2013**;188(10):1224–1231.
117. Allen EK, Koeppl, AF, and Hendley, JO, et al. Characterization of the nasopharyngeal microbiota in health and during rhinovirus challenge. *Microbiome.* **2014**;2(1):22.
118. Lu H-F, Li, A, and Zhang, T, et al. Disordered oropharyngeal microbial communities in H7N9 patients with or without secondary bacterial lung infection. *Emerg Microbes Infect.* **2017**;6(1):1–11.
119. Leung R-K, Zhou J-W, Guan W, et al. Modulation of potential respiratory pathogens by pH1N1 viral infection. *Clin Microbiol Infect.* **2013**;19(10):930–935.
120. Rogers GB, Shaw D, Marsh RL, et al. Respiratory microbiota: addressing clinical questions, informing clinical practice. *Thorax.* **2015**;70 (1):74–81.
121. Qin N, Zheng, B, and Yao, J, et al. Influence of H7N9 virus infection and associated treatment on human gut microbiota. *Sci Rep.* **2015**;5:14771.
122. Saitou M, Nemoto D, Utano K, et al. Identification of intestinal abnormalities in patients with active pulmonary tuberculosis using small bowel capsule endoscopy. *Endosc Int Open.* **2018**;6 (9):E1103.
123. Luo M, Liu Y, Wu P, et al. Alternation of gut microbiota in patients with pulmonary tuberculosis. *Front Physiol.* **2017**;8:822.
124. Zhang D, Li, S, and Wang, N, et al. The cross-talk between gut microbiota and lungs in common lung diseases. *Front Microbiol.* **2020**;11: 301.
125. Neu U, Mainou BA, Evans MJ. Virus interactions with bacteria: partners in the infectious dance. *PLoS Pathog.* **2020**;16(2): e1008234.
126. Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review. *J Infect Public Health.* **2018**;11(1):9–17.
127. Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. *Nat Rev Microbiol.* **2009**;7(3):226–236.
128. Zeppa SD, Agostini, D, and Piccoli, G, et al. Gut microbiota status in COVID-19: an unrecognized player? *Front Cell Infect Microbiol.* **2020**;10 576551 .
129. Ichinohe T, Pang IK, Kumamoto Y, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. *Proc Natl Acad Sci.* **2011**;108(13):5354–5359.
130. Abt MC, Osborne L, Monticelli L, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. **2012**;37 (1):158–170.
131. Allie SR, Bradley JE, Mudunuru U, et al. The establishment of resident memory B cells in the lung requires local antigen encounter. *Nat Immunol.* **2019**;20(1):97–108.

132. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov Ther.* **2020**;14(1):58–60.
133. Lv L, Gu S, Jiang H, et al. Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features. *Commun Biol.* **2021**;4(1):480.
134. Forbes JD, Bernstein CN, Tremlett H, et al. A fungal world: could the gut mycobiome be involved in neurological disease? *Front Microbiol.* **2019**;9:3249.
135. Lv L, Gu S, and Jiang, H, et al. Gut mycobiota alterations in patients with COVID-19 and H1N1 and their associations with clinical features *Commun Biol.* **2021**;4(1): 480 .
136. Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. *Gastroenterology.* **2020**;159(3):944–955. e8.
137. Gou W, Fu, Y, and Yue, L, et al., Gut microbiota may underlie the predisposition of healthy individuals to COVID-19. *MedRxiv.* **2020**.
138. Zuo T, Liu, Q, and Zhang, F, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. *Gut.* **2021**;70(2):276–284.
139. Zhou Y, Shi X, Fu W, et al. Gut microbiota dysbiosis correlates with abnormal immune response in moderate COVID-19 patients with fever. *J Inflamm Res.* **2021**;14:2619–2631.
140. Gu S, Chen Y, Wu Z, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 Influenza. *Clin Infect Dis.* **2020**;71(10):2669–2678.
141. Yeoh YK, Zuo T, Lui GC-Y, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. *Gut.* **2021**;70(4):698–706.
142. Tang L, Gu S, Gong Y, et al. Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity. *Engineering.* **2020**;6(10):1178–1184.
143. Khatiwada S, Subedi A. Lung microbiome and coronavirus disease 2019 (COVID-19): possible link and implications. *Hum Microbiome J.* **2020**;17:100073.
144. Kalina U, Koyama N, Hosoda T, et al. Enhanced production of IL-18 in butyrate-treated intestinal epithelium by stimulation of the proximal promoter region. *Eur J Immunol.* **2002**;32(9):2635–2643.
145. Domínguez-Cherit G, Lapinsky SE, and Macias, AE, et al. Critically ill patients with 2009 influenza A (H1N1) in Mexico. *JAMA.* **2009**;302(17):1880–1887.
146. Yasui H, Kiyoshima J, Hori TJCDLI. Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed *Lactobacillus casei* Shirota. *Clin Vaccin Immunol.* **2004**;11(4):675–679.
147. Tomosada Y, Chiba E, Zelaya H, et al. Nasally administered *Lactobacillus rhamnosus* strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. *BMC Immunol.* **2013**;14(1):40.
148. Mailliard RB, Son Y-I, Redlinger R, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. *J Immunol.* **2003**;171(5):2366–2373.
149. Kitazawa H, Villena JJFII. Modulation of respiratory TLR3-anti-viral response by probiotic microorganisms: lessons learned from *Lactobacillus rhamnosus* CRL1505. *Front Immunol.* **2014**;5:201.
150. Yilla M, Harcourt BH, Hickman CJ, et al. SARS-coronavirus replication in human peripheral monocytes/macrophages. *Virus Res.* **2005**;107(1):93–101.
151. Cinatl J Jr., Hoefer G, Morgenstern B, et al. Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus. *Cell Mol Life Sci.* **2004**;61(16):2100–12.
152. Spiegel M, Schneider K, Weber F, et al. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. *J Gen Virol.* **2006**;87(7):1953–60.
153. Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proc Natl Acad Sci U S A.* **2005**;102(33):11876–11881.
154. Fischer DD, Kandasamy S, Paim FC, et al. Protein malnutrition alters tryptophan and angiotensin-converting enzyme 2 homeostasis and adaptive immune responses in human rotavirus-infected gnotobiotic pigs with human infant fecal microbiota transplant. *Clin Vaccin Immunol.* **2017**;24(8):e00172–17.
155. Vighi G, Marcucci F, Sensi L, et al. Allergy and the gastrointestinal system. *Clin Exp Immunol.* **2008**;153(Suppl 1):3–6.
156. Mikelkaar M, Lazar V, Onderdonk A, et al. Do probiotic preparations for humans really have efficacy? *Microb Ecol Health Dis.* **2011**;22(1):10128.
157. Kong YH, Shi, Q, and Han, N, et al. Structural modulation of gut microbiota in rats with allergic bronchial asthma treated with recuperating lung decoction. *Biomed Environ Sci.* **2016**;29(8):574–583.
158. Villena J, Salva S, Barbieri N, et al. Immunobiotics for the Prevention of Bacterial and Viral Respiratory Infections Probiotics 1. Boca Raton: CRC Press. **2013**:128–168. 9780429090684 .
159. Mullish BH, Marchesi JR, McDonald JAK, et al. Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics? *Gut Microbes.* **2021**;13(1):1900997.
160. Bron PA, Kleerebezem M, Brummer R-J, et al. Can probiotics modulate human disease by impacting intestinal barrier function? *Br J Nutr.* **2017**;117(1):93–107.
161. Davani-Davari D, Negahdaripour M, Karimzadeh I, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. *Foods.* **2019**;8(3):92.
162. Olaimat AN, Aolymat I, Al-Holy M, et al. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. *NPJ Science Food.* **2020**;4(1):1–7.
163. Fujiwara S, Seto Y, Kimura A, et al. Establishment of orally-administered *Lactobacillus gasseri* SBT2055SR in the gastrointestinal tract of humans and its influence on intestinal microflora and metabolism. *J Appl Microbiol.* **2001**;90(3):343–352.
164. Takahashi H, Fujita T, Suzuki Y, et al. Monitoring and survival of *Lactobacillus gasseri* SBT2055 in the human intestinal tract. *Microbiol Immunol.* **2006**;50(11):867–870.
165. Sakai F, Hosoya T, Ono-Ohmachi A, et al. *Lactobacillus gasseri* SBT2055 induces TGF- β expression in dendritic cells and activates TLR2 signal to produce IgA in the small intestine. *PLoS One.* **2014**;9(8):e105370.
166. Nakayama Y, Moriya T, Sakai F, et al. Oral administration of *Lactobacillus gasseri* SBT2055 is effective for preventing influenza in mice. *Sci Rep.* **2014**;4:4638.
167. Eguchi K, Fujitani N, Nakagawa H, et al. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium *Lactobacillus gasseri* SBT2055. *Sci Rep.* **2019**;9(1):1–11.
168. Hori T, Kiyoshima J, Shida K, et al. Effect of intranasal administration of *Lactobacillus casei* Shirota on influenza virus infection of upper respiratory tract in mice. *Clin Diagn Lab Immunol.* **2001**;8(3):593–597.
169. Vickers NJCB. Animal communication: when i'm calling you, will you answer too? *Curr Biol.* **2017**;27(14):R713–15.
170. Gabryszewski SJ, Bachar O, Dyer KD, et al. *Lactobacillus*-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. *J Immunol.* **2011**;186(2):1151–1161.
171. Villena J, Barbieri N, Salva S, et al. Enhanced immune response to pneumococcal infection in malnourished mice nasally treated with heat-killed *Lactobacillus casei*. *Microbiol Immunol.* **2009**;53(11):636–46.
172. Weiss G, Rasmussen S, Zeuthen LH, et al. *Lactobacillus acidophilus* induces virus immune defence genes in murine dendritic cells by a Toll-like receptor-2-dependent mechanism. *Immunology.* **2010**;131(2):268–81.
173. Khailova L, Petrie B, Baird CH, et al. *Lactobacillus rhamnosus* GG and *Bifidobacterium longum* attenuate lung injury and inflammatory response in experimental sepsis. *PLoS One.* **2014**;9(5):e97861.
174. Iwabuchi N, Xiao J-Z, Yaeshima T, et al. Oral administration of *Bifidobacterium longum* ameliorates influenza virus infection in mice. *Biol Pharm Bull.* **2011**;34(8):1352–1355.
175. Kawahara T, Takahashi T, Oishi K, et al. Consecutive oral administration of *Bifidobacterium longum* MM-2 improves the defense system

- against influenza virus infection by enhancing natural killer cell activity in a murine model. *Microbiol Immunol*. 2015;59(1):1–12.
176. Namba K, Hatano M, Yaeshima T, et al. Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly. *Biosci Biotechnol Biochem*. 2010;74(5):939–945.
 177. Furuhashi K, Suda T, Hasegawa H, et al. Mouse lung CD103+ and CD11bhigh dendritic cells preferentially induce distinct CD4+ T-cell responses. *Am J Respir Cell Mol Biol*. 2012;46(2):165–172.
 178. Gleeson M, Pyne DB. Respiratory inflammation and infections in high-performance athletes. *Immunol Cell Biol*. 2016;94(2):124–131.
 179. Van Puyenbroeck K, Hens N, Coenen S, et al. Efficacy of daily intake of *Lactobacillus casei* Shirota on respiratory symptoms and influenza vaccination immune response: a randomized, double-blind, placebo-controlled trial in healthy elderly nursing home residents. *Am J Clin Nutr*. 2012;95(5):1165–1171.
 180. Sindhu KN, Sowmyanarayanan TV, Paul A, et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with *Lactobacillus rhamnosus* GG: a randomized, double-blind, placebo-controlled trial. *Clin Infect Dis*. 2014;58(8):1107–1115.
 181. Hirose Y, Murosaki S, and Yamamoto, Y, et al. Daily intake of heat-killed *Lactobacillus plantarum* L-137 augments acquired immunity in healthy adults. *J Nutr*. 2006;136(12):3069–3073.
 182. Maeda N, Nakamura, R, and Hirose, Y, et al. Oral administration of heat-killed *Lactobacillus plantarum* L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. *Int Immunopharmacol*. 2009;9(9):1122–1125.
 183. Izumo T, Maekawa, T, and Ida, M, et al. Effect of intranasal administration of *Lactobacillus pentosus* S-PT84 on influenza virus infection in mice. *Int Immunopharmacol*. 2010;10(9):1101–1106.
 184. Fujimura KE, Demoor T, Rauch M, et al. House dust exposure mediates gut microbiome *Lactobacillus* enrichment and airway immune defense against allergens and virus infection. *Proc Natl Acad Sci U S A*. 2014;111(2):805–810.
 185. Yasui H, Kiyoshima J, Hori T, et al. Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. *Clin Diagn Lab Immunol*. 1999;6(2):186–192.
 186. Bandoro C, Runstadler JA, Lowen AC. Bacterial lipopolysaccharide destabilizes influenza viruses. *MSphere*. 2017;2(5):e00267–17.
 187. Deitch EA. Gut-origin sepsis: evolution of a concept. *Surgeon*. 2012;10(6):350–356.
 188. Bradley KC, Finsterbusch K, Schnepf D, et al. Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection. *Cell Rep*. 2019;28(1):245–256. e4.
 189. Albenberg LG, Wu GDJG. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. *Gastroenterology*. 2014;146(6):1564–1572.
 190. Varraso R, Chiuve SE, Fung TT, et al. Alternate Healthy Eating Index 2010 and risk of chronic obstructive pulmonary disease among US women and men: prospective study. *BMJ*. 2015;350:h286.
 191. King DE, Egan BM, Woolson RF, et al. Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level. *Arch Intern Med*. 2007;167(5):502–506.
 192. Kazemian N, Kao D, Pakpour S. Fecal microbiota transplantation during and post-COVID-19 pandemic. *Int J Mol Sci*. 2021;22(6):3004.
 193. Liu F, Ye S, Zhu X, et al. Gastrointestinal disturbance and effect of fecal microbiota transplantation in discharged COVID-19 patients. *J Med Case Rep*. 2021;15(1):1–9.
 194. Stewart CJ, Ajami NJ, O'Brien JL, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature*. 2018;562(7728):583–588.
 195. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. *PLoS Pathog*. 2014;10(2):e1003829.
 196. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. *Immunity*. 2020;52(6):910–941.
 197. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet*. 2020;395(10239):1771–1778.
 198. Chhibber-Goel J, Gopinathan S, Sharma A. Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections? *Gut Pathog*. 2021;13(1):1–6.
 199. Goncalves Mendes Neto A, Lo KB, Wattoo A, et al. Bacterial infections and patterns of antibiotic use in patients with COVID-19. *J Med Virol*. 2021;93(3):1489–1495.
 200. Vila AV, Collij, V, and Sanna, S, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. *Nat Commun*. 2020;11(1):1–11.